Company intelligence / Profile preview
SunRock Biopharma
Santiago de Compostela, La Coruna, Spain
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
SunRock Biopharma has developed a portfolio of therapeutic antibodies targeting CCR9 and HER3. Their lead candidate SRB1 targeting CCR9 has reached IND Application stage, while several other programs targeting HER3 are in preclinical development. The company has established partnerships with Debiopharm to develop antibody-drug conjugates.
- Therapeutic areas
- OncologyHematology
- Modalities
- Therapeutic antibodiesMonoclonal antibodiesBispecific antibodiesBifunctional antibodiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Debiopharm (Swiss biopharmaceutical company)
Beyond the preview
Go deeper on SunRock Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SunRock Biopharma.